$CLNN
Clene Inc. Stock $clnn

$clnn Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000095017022017214 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$174.0K	$35.00K	$30.00K
YoY Change	58.18%	-82.59%	-85.92%
Cost Of Revenue	$19.00K	$0.00	$0.00
YoY Change	35.71%	-100.0%	-100.0%
Gross Profit	$155.0K	$35.00K	$30.00K
YoY Change	61.46%	-109.89%	-200.0%
Gross Profit Margin	89.08%	100.0%	100.0%
Selling, General & Admin	$3.490M	$4.397M	$4.757M
YoY Change	-20.16%	-36.46%	-8.34%
% of Gross Profit	2251.61%	12562.86%	15856.67%
Research & Development	$6.403M	$9.166M	$8.580M
YoY Change	7.69%	41.63%	36.73%
% of Gross Profit	4130.97%	26188.57%	28600.0%
Depreciation & Amortization	$233.0K	$287.0K	$195.0K
YoY Change	-0.85%	12.55%	-20.08%
% of Gross Profit	150.32%	820.0%	650.0%
Operating Expenses	$9.979M	$13.63M	$13.37M
YoY Change	-5.38%	-2.48%	12.24%
Operating Profit	-$9.805M	-$13.60M	-$13.34M
YoY Change	-6.17%	-1.31%	14.03%
Interest Expense	-$2.448M	$751.0K	$782.0K
YoY Change	-106.97%	2788.46%	41.92%
% of Operating Profit
Other Income/Expense, Net	-$1.171M	$9.061M	-$18.00K
YoY Change	-127.86%	-12.47%	-99.94%
Pretax Income	-$10.98M	-$4.534M	-$13.35M
YoY Change	-138.01%	32.46%	-66.47%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$10.98M	-$4.534M	-$13.35M
YoY Change	-137.92%	35.3%	-66.41%
Net Earnings / Revenue	-6308.05%	-12954.29%	-44513.33%
Basic Earnings Per Share	-$0.17	-$0.07	-$0.21
Diluted Earnings Per Share	-$0.17	-$0.07	-$212.5K
COMMON SHARES
Basic Shares Outstanding	63.50M	63.34M	63.14M
Diluted Shares Outstanding	63.51M	63.34M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.23M	$26.29M	$36.52M
YoY Change	-73.19%	-58.28%	-23.99%
Cash & Equivalents	$7.267M	$7.253M	$12.90M
Short-Term Investments	$8.966M	$19.03M	$23.59M
Other Short-Term Assets	$3.491M	$3.045M	$3.978M
YoY Change	-0.82%	32.62%	64.38%
Inventory	$38.00K	$107.0K	$38.00K
Prepaid Expenses			$5.895M
Receivables	$126.0K	$0.00
Other Receivables	$1.598M	$2.149M	$1.917M
Total Short-Term Assets	$21.49M	$31.59M	$42.45M
YoY Change	-67.14%	-53.66%	-20.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.753M	$8.089M	$5.914M
YoY Change	28.57%	57.8%	13.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$58.00K	$58.00K	$58.00K
YoY Change	0.0%
Total Long-Term Assets	$14.52M	$12.96M	$10.91M
YoY Change	89.93%	152.73%	110.25%
TOTAL ASSETS
Total Short-Term Assets	$21.49M	$31.59M	$42.45M
Total Long-Term Assets	$14.52M	$12.96M	$10.91M
Total Assets	$36.00M	$44.54M	$53.36M
YoY Change	-50.7%	-39.22%	-8.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.454M	$4.526M	$3.313M
YoY Change	237.63%	295.98%	347.7%
Accrued Expenses	$2.136M	$2.566M	$1.541M
YoY Change	-36.79%	-12.75%	-47.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$97.00K	$123.0K	$139.0K
YoY Change	-36.6%	-22.64%	-0.71%
Total Short-Term Liabilities	$6.154M	$7.655M	$5.466M
YoY Change	27.39%	69.4%	33.64%
LONG-TERM LIABILITIES
Long-Term Debt	$20.53M	$20.32M	$19.44M
YoY Change	6.41%	36.25%	848.24%
Other Long-Term Liabilities	$18.64M	$17.14M	$26.44M
YoY Change	-56.82%	-78.48%	-70.04%
Total Long-Term Liabilities	$39.17M	$37.45M	$45.88M
YoY Change	-37.28%	-60.39%	-49.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.154M	$7.655M	$5.466M
Total Long-Term Liabilities	$39.17M	$37.45M	$45.88M
Total Liabilities	$45.32M	$45.11M	$51.34M
YoY Change	-32.71%	-54.54%	-45.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$192.2M	-$181.2M	-$176.7M
YoY Change
Common Stock	$6.000K	$6.000K	$6.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.319M	-$563.0K	$2.017M
YoY Change
Total Liabilities & Shareholders Equity	$36.00M	$44.54M	$53.36M
YoY Change	-50.7%	-39.22%	-8.83%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$10.98M	-$4.534M	-$13.35M
YoY Change	-137.92%	35.3%	-66.41%
Depreciation, Depletion And Amortization	$233.0K	$287.0K	$195.0K
YoY Change	-0.85%	12.55%	-20.08%
Cash From Operating Activities	-$8.481M	-$9.730M	-$13.10M
YoY Change	16.1%	13.76%	42.39%
INVESTING ACTIVITIES
Capital Expenditures	-$1.654M	-$888.0K	$936.0K
YoY Change	586.31%	303.64%	361.08%
Acquisitions
YoY Change
Other Investing Activities	$10.07M	$4.553M	-$23.59M
YoY Change
Cash From Investing Activities	$8.411M	$3.665M	-$24.52M
YoY Change	-3590.04%	-1765.91%	11979.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	92.00K	548.0K	235.0K
YoY Change	-98.24%	-97.7%	-112.39%
NET CHANGE
Cash From Operating Activities	-8.481M	-9.730M	-13.10M
Cash From Investing Activities	8.411M	3.665M	-24.52M
Cash From Financing Activities	92.00K	548.0K	235.0K
Net Change In Cash	22.00K	-5.517M	-37.36M
YoY Change	-100.95%	-136.72%	232.54%
FREE CASH FLOW
Cash From Operating Activities	-$8.481M	-$9.730M	-$13.10M
Capital Expenditures	-$1.654M	-$888.0K	$936.0K
Free Cash Flow	-$6.827M	-$8.842M	-$14.04M
YoY Change	-3.36%	6.11%	49.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	01-39834
	dei	Entity Registrant Name EntityRegistrantName	CLENE INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2828339
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6550 South Millrock Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite G50
	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84121
	dei	City Area Code CityAreaCode	801
	dei	Local Phone Number LocalPhoneNumber	676-9695
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	CLNN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	clnn	Common Stock Warrant Liability Recorded At Issuance Of Notes Payable CommonStockWarrantLiabilityRecordedAtIssuanceOfNotesPayable
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Entity Central Index Key EntityCentralIndexKey	0001822791
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63501984
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7253000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50288000
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	19033000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	49000
CY2022Q2	us-gaap	Inventory Net InventoryNet	107000
CY2021Q4	us-gaap	Inventory Net InventoryNet	41000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5194000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4205000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	31587000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	54583000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4808000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3250000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8089000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2022Q2	us-gaap	Assets Assets	44542000
CY2021Q4	us-gaap	Assets Assets	63063000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4526000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1923000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2566000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3610000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	440000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347000
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	123000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	146000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7655000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6026000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5858000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4370000
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	55000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	97000
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	15551000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14484000
CY2022Q2	clnn	Convertible Note Payable ConvertibleNotePayable	4709000
CY2021Q4	clnn	Convertible Note Payable ConvertibleNotePayable	4598000
CY2022Q2	clnn	Common Stock Warrant Liability CommonStockWarrantLiability	167000
CY2021Q4	clnn	Common Stock Warrant Liability CommonStockWarrantLiability	474000
CY2022Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	9847000
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	18100000
CY2022Q2	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	1263000
CY2021Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	2317000
CY2022Q2	us-gaap	Liabilities Liabilities	45105000
CY2021Q4	us-gaap	Liabilities Liabilities	50466000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63421908
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63421908
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62312097
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62312097
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	6000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	180534000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175659000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181189000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163301000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	86000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	233000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-563000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44542000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63063000
CY2022Q2	us-gaap	Revenues Revenues	35000
CY2021Q2	us-gaap	Revenues Revenues	201000
	us-gaap	Revenues Revenues	65000
	us-gaap	Revenues Revenues	414000
CY2022Q2	clnn	Costs Of Revenue CostsOfRevenue	0
CY2021Q2	clnn	Costs Of Revenue CostsOfRevenue	555000
	clnn	Costs Of Revenue CostsOfRevenue	0
	clnn	Costs Of Revenue CostsOfRevenue	798000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9166000
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6472000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17746000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12747000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4464000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6949000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9250000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12339000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	13630000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	13976000
	us-gaap	Operating Expenses OperatingExpenses	26996000
	us-gaap	Operating Expenses OperatingExpenses	25884000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13595000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13775000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26931000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25470000
CY2022Q2	us-gaap	Interest Expense InterestExpense	751000
CY2021Q2	us-gaap	Interest Expense InterestExpense	26000
	us-gaap	Interest Expense InterestExpense	1533000
	us-gaap	Interest Expense InterestExpense	577000
CY2022Q2	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	0
CY2021Q2	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	0
	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	0
	clnn	Gain On Extinguishment Of Debt GainOnExtinguishmentOfDebt	647000
CY2022Q2	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0
CY2021Q2	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	420000
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0
CY2022Q2	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	20000
CY2021Q2	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	133000
	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	2000
	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	133000
CY2022Q2	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	8310000
CY2021Q2	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	8640000
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	8253000
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	-16970000
CY2022Q2	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	1066000
CY2021Q2	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	1232000
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	1054000
	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	-1729000
CY2022Q2	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-356000
CY2021Q2	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-375000
	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-655000
	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-714000
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	60000
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	192000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9061000
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10352000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9043000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17781000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4534000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3423000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17888000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43251000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-72000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-144000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4534000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3351000
	us-gaap	Net Income Loss NetIncomeLoss	-17888000
	us-gaap	Net Income Loss NetIncomeLoss	-43107000
CY2022Q2	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	37000
CY2021Q2	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	87000
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-110000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-61000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-60000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-37000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	147000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	61000
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	147000
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	37000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4681000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3412000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18035000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43144000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63335271
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63335271
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61165018
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61165018
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63095400
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63095400
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60919340
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60919340
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000
CY2022Q1	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	267000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2202000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000
CY2022Q1	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	50000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-13354000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	2017000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2184000
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-37000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	100000
CY2022Q2	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	-110000
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4534000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-563000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	341000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3265000
CY2021Q1	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	24000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-39756000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-36076000
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9250000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	58000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4255000
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0
CY2021Q2	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	-61000
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-3351000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-25925000
	us-gaap	Net Income Loss NetIncomeLoss	-17888000
	us-gaap	Net Income Loss NetIncomeLoss	-43107000
	us-gaap	Depreciation Depreciation	482000
	us-gaap	Depreciation Depreciation	499000
	us-gaap	Other Noncash Expense OtherNoncashExpense	183000
	us-gaap	Other Noncash Expense OtherNoncashExpense	46000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-133000
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	8253000
	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	-16970000
	clnn	Changes In Fair Value Of Initial Shareholders Contingent Earnout ChangesInFairValueOfInitialShareholdersContingentEarnout	1054000
	clnn	Changes In Fair Value Of Initial Shareholders Contingent Earnout ChangesInFairValueOfInitialShareholdersContingentEarnout	-1729000
	us-gaap	Share Based Compensation ShareBasedCompensation	4386000
	us-gaap	Share Based Compensation ShareBasedCompensation	7520000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	647000
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	420000
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	442000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
	us-gaap	Paid In Kind Interest PaidInKindInterest	72000
	us-gaap	Paid In Kind Interest PaidInKindInterest	389000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-49000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	48000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	66000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-137000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	989000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1528000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1528000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	565000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1044000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	125000
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	119000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-240000
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-111000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22814000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17713000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	24549000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2500000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3016000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1824000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	420000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20857000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-420000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	284000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	108000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	83000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	694000
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	15000000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	30000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	471000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5000
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9250000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1901000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	783000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21898000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-147000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-33000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-43035000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3732000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50346000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59275000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7311000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63007000
CY2022Q2	us-gaap	Cash Cash	7253000
CY2021Q2	us-gaap	Cash Cash	63007000
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	58000
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	0
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7311000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63007000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2343000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
	clnn	Lease Incentive Realized LeaseIncentiveRealized	500000
	clnn	Lease Incentive Realized LeaseIncentiveRealized	0
	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	602000
	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	0
	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	305000
	clnn	Reclassification Of Common Stock Warrant Liability To Permanent Equity ReclassificationOfCommonStockWarrantLiabilityToPermanentEquity	0
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1075000
	clnn	Common Stock Warrant Liability Recorded At Issuance Of Notes Payable CommonStockWarrantLiabilityRecordedAtIssuanceOfNotesPayable	1457000
	clnn	Cash Paid For Interest Expense CashPaidForInterestExpense	1013000
	clnn	Cash Paid For Interest Expense CashPaidForInterestExpense	188000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13600000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13800000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26900000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25500000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181200000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163300000
CY2022Q2	clnn	Cash Cash Equivalents Restricted Cash And Marketable Securities CashCashEquivalentsRestrictedCashAndMarketableSecurities	26300000
CY2021Q4	clnn	Cash Cash Equivalents Restricted Cash And Marketable Securities CashCashEquivalentsRestrictedCashAndMarketableSecurities	50300000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22800000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17700000
CY2021Q2	clnn	Minimum Cash Balance For Loan Covenant MinimumCashBalanceForLoanCovenant	5000000.0
CY2022Q2	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	0
CY2021Q2	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	200000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.</span></p>
CY2020Q4	clnn	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	9400000
CY2020Q4	clnn	Net Proceeds From Reverse Recapitalization NetProceedsFromReverseRecapitalization	3500000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p>
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	93000
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	26000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15000
	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	0
	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	200000
CY2020Q4	clnn	Shares Issued For Payment Of Offering Costs SharesIssuedForPaymentOfOfferingCosts	644164
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2400000
CY2021Q3	us-gaap	Incentive To Lessee IncentiveToLessee	1000000.0
CY2022Q2	clnn	Lease Incentive Recorded Construction In Progress LeaseIncentiveRecordedConstructionInProgress	1000000.0
CY2021Q4	clnn	Lease Incentive Recorded Construction In Progress LeaseIncentiveRecordedConstructionInProgress	500000
CY2021Q4	clnn	Operating Lease Obligations Weighted Average Interest Rate OperatingLeaseObligationsWeightedAverageInterestRate	0.096
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y9M18D
	clnn	Clene Nanomedicine Contingent Earn Out Milestone1 Shares CleneNanomedicineContingentEarnOutMilestone1Shares	3333333
	clnn	Clene Nanomedicine Contingent Earnout Milestone1 Price CleneNanomedicineContingentEarnoutMilestone1Price	15.00
	clnn	Clene Nanomedicine Contingent Earnout Milestone2 Shares CleneNanomedicineContingentEarnoutMilestone2Shares	2500000
	clnn	Clene Nanomedicine Contingent Earnout Milestone2 Price CleneNanomedicineContingentEarnoutMilestone2Price	20.00
	clnn	Clene Nanomedicine Contingent Earnout Milestone3 Shares CleneNanomedicineContingentEarnoutMilestone3Shares	2500000
	clnn	Total Clene Nanomedicine Contingent Earnout Shares TotalCleneNanomedicineContingentEarnoutShares	8346185
	clnn	Initial Shareholders Contingent Earnout Milestone One Shares InitialShareholdersContingentEarnoutMilestoneOneShares	375000
	clnn	Initial Shareholders Contingent Earnout Milestone2 Shares InitialShareholdersContingentEarnoutMilestone2Shares	375000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Milestone Three Shares Cancelled CleneNanomedicineContingentEarnoutMilestoneThreeSharesCancelled	2503851
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19120000
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	87000
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	19033000
	clnn	Debt Securities Available For Sale Maturity Period DebtSecuritiesAvailableForSaleMaturityPeriod	P1Y
CY2022Q2	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	2500000
CY2022Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3000000.0
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The lease has an initial ten-year term and provides us the right and option to extend or renew for two periods of five years each. In accordance with ASC 842, Leases, the payments to be made in option periods have not been recognized as part of the right-of-use asset or lease liability because we do not assess the exercise of the option to be reasonably certain.
CY2022Q1	clnn	Operating Leases Rightof Use Assets OperatingLeasesRightofUseAssets	2300000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2300000
CY2022Q1	clnn	Terminated Right Of Use Asset TerminatedRightOfUseAsset	600000
CY2022Q1	clnn	Terminated Operating Lease Liability TerminatedOperatingLeaseLiability	1000000.0
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	400000
CY2022Q2	clnn	Australia Research And Development Credit Receivable AustraliaResearchAndDevelopmentCreditReceivable	-2149000
CY2021Q4	clnn	Australia Research And Development Credit Receivable AustraliaResearchAndDevelopmentCreditReceivable	-1564000
CY2022Q2	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	1623000
CY2021Q4	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	2237000
CY2022Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1422000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	404000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5194000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4205000
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3410000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3327000
CY2022Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	166000
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	147000
CY2022Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	459000
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	0
CY2022Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3956000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3943000
CY2022Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	4865000
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2052000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12856000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9469000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4767000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4297000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8089000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2022Q2	clnn	Operating Lease Obligations Weighted Average Interest Rate OperatingLeaseObligationsWeightedAverageInterestRate	0.096
CY2022Q2	us-gaap	Depreciation Depreciation	287000
CY2021Q2	us-gaap	Depreciation Depreciation	255000
	us-gaap	Depreciation Depreciation	482000
	us-gaap	Depreciation Depreciation	499000
CY2021Q4	clnn	Finance Lease Work In Process Gross FinanceLeaseWorkInProcessGross	228000
CY2022Q2	clnn	Finance Lease Liability Gross FinanceLeaseLiabilityGross	636000
CY2021Q4	clnn	Finance Lease Liability Gross FinanceLeaseLiabilityGross	636000
CY2022Q2	clnn	Accumulated Depreciation Depletion And Amortization Leases AccumulatedDepreciationDepletionAndAmortizationLeases	-285000
CY2021Q4	clnn	Accumulated Depreciation Depletion And Amortization Leases AccumulatedDepreciationDepletionAndAmortizationLeases	-244000
CY2022Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1285000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2049000
CY2022Q2	clnn	Accrued Cro Fees AccruedCROFees	694000
CY2021Q4	clnn	Accrued Cro Fees AccruedCROFees	718000
CY2022Q2	clnn	Deferred Grant Funds DeferredGrantFunds	520000
CY2021Q4	clnn	Deferred Grant Funds DeferredGrantFunds	520000
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	67000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	323000
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2566000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3610000
CY2021Q3	clnn	Operating Leases Rightof Use Assets OperatingLeasesRightofUseAssets	2400000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2022Q2	clnn	Finance Lease Laboratory Equipment Gross FinanceLeaseLaboratoryEquipmentGross	408000
CY2021Q4	clnn	Finance Lease Laboratory Equipment Gross FinanceLeaseLaboratoryEquipmentGross	408000
CY2022Q2	clnn	Finance Lease Work In Process Gross FinanceLeaseWorkInProcessGross	228000
CY2022Q2	clnn	Finance Lease Liability Net FinanceLeaseLiabilityNet	351000
CY2021Q4	clnn	Finance Lease Liability Net FinanceLeaseLiabilityNet	392000
CY2022Q2	clnn	Finance Lease Obligations Weightedaverage Interest Rate FinanceLeaseObligationsWeightedaverageInterestRate	0.091
CY2021Q4	clnn	Finance Lease Obligations Weightedaverage Interest Rate FinanceLeaseObligationsWeightedaverageInterestRate	0.088
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	21000
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	36000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	41000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	73000
CY2022Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
CY2021Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	7000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	15000
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	209000
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	70000
	us-gaap	Operating Lease Cost OperatingLeaseCost	439000
	us-gaap	Operating Lease Cost OperatingLeaseCost	140000
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	54000
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	116000
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	108000
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	20000
	us-gaap	Variable Lease Cost VariableLeaseCost	173000
	us-gaap	Variable Lease Cost VariableLeaseCost	39000
CY2022Q2	us-gaap	Lease Cost LeaseCost	339000
CY2021Q2	us-gaap	Lease Cost LeaseCost	187000
	us-gaap	Lease Cost LeaseCost	659000
	us-gaap	Lease Cost LeaseCost	383000
CY2022Q2	clnn	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-612000
CY2021Q2	clnn	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-295000
CY2022Q2	clnn	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-6000
CY2021Q2	clnn	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-15000
CY2022Q2	clnn	Finance Cash Flows From Finance Leases FinanceCashFlowsFromFinanceLeases	-65000
CY2021Q2	clnn	Finance Cash Flows From Finance Leases FinanceCashFlowsFromFinanceLeases	-83000
	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	849215
CY2022Q2	clnn	Total Term Loans TotalTermLoans	21454000
CY2021Q4	clnn	Total Term Loans TotalTermLoans	20736000
CY2022Q2	clnn	Accrued And Unpaid Interest AccruedAndUnpaidInterest	2000
CY2021Q4	clnn	Accrued And Unpaid Interest AccruedAndUnpaidInterest	0
CY2022Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1196000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1654000
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-4709000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-4598000
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	15551000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14484000
	clnn	Schedule Of Future Payments Net Of Unamortized Debt Discounts ScheduleOfFuturePaymentsNetOfUnamortizedDebtDiscounts	<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Future payments under the 2021 Avenue Loan, net of unamortized debt discounts, if Avenue does not exercise the Conversion Feature, and under the 2022 MD Loan, net of unamortized debt discounts, are as follows:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.589%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:13.082%;"/> <td style="width:1.0%;"/> <td style="width:1.623%;"/> <td style="width:1.0%;"/> <td style="width:13.082%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2021 Avenue Loan</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;">2022 MD Loan</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022 (remainder)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">6,667</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">13,333</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">368</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2026</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">326</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2027</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Thereafter</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Subtotal of future principal payments</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">20,000</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">694</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Accrued and unpaid interest</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Less unamortized debt issuance costs and original issue discounts</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1,166</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">18,834</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">666</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table>
CY2022Q2	clnn	Number Of Shares Issuable NumberOfSharesIssuable	4477045
CY2021Q4	clnn	Number Of Shares Issuable NumberOfSharesIssuable	4477045
CY2022Q2	us-gaap	Shares Issued SharesIssued	2407500
	clnn	Company Warrant Redemption Right CompanyWarrantRedemptionRight	We may redeem the outstanding warrants, in whole and not in part, at $0.01 per warrant if the last sales price of our Common Stock equals or exceeds $16.50 per share for any twenty trading days within a thirty-trading day period.
	clnn	Warrant Redemption Price Per Share WarrantRedemptionPricePerShare	0.01
CY2022Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	16.50
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.35
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M25D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	21082000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2755973
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.01
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.54
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y11M19D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8718000
CY2022Q2	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber	6161852
CY2022Q2	clnn	Weighted Average Exercise Price Per Share Option Vested And Exercisable WeightedAverageExercisePricePerShareOptionVestedAndExercisable	2.10
	clnn	Weighted Average Exercise Price Weighted Average Remaining Term Years Options Vested And Eexercisable Ending WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding	P4Y10M2D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8711000
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	12071276
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.54
	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1	P6Y11M19D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	8718000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3398000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2574000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-16355000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-41295000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1136000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-849000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1533000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1956000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4534000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3423000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17888000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43251000
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	4500
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2184000
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4255000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4386000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7520000
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2184000
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4255000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4386000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7520000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10395027
	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted	P9Y7M24D
	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted	0
	clnn	Share Based Compensation Arrangement Number Of Options Exercised ShareBasedCompensationArrangementNumberOfOptionsExercised	1044448
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.27
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2348000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	35276
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.07
	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12071276
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	20100000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18300000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M25D
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.24
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.44
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	167000
CY2022Q2	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	9847000
CY2022Q2	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	1263000
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	736000
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	474000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	18100000
CY2021Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	2317000
	clnn	Fair Value Amortized Cost FairValueAmortizedCost	18800000
CY2022Q2	us-gaap	Notes Payable NotesPayable	14100000
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	4700000
CY2021	clnn	Fair Value Amortized Cost FairValueAmortizedCost	18300000
CY2021Q4	us-gaap	Notes Payable NotesPayable	13700000
CY2021	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	4600000
CY2022Q2	clnn	Fair Value Of Conversion Feature FairValueOfConversionFeature	300000
CY2021Q4	clnn	Fair Value Of Conversion Feature FairValueOfConversionFeature	800000
CY2022Q2	clnn	Common Stock Issuable Upon Achievement Of Milestones CommonStockIssuableUponAchievementOfMilestones	5842334
CY2021Q4	clnn	Common Stock Issuable Upon Achievement Of Milestones CommonStockIssuableUponAchievementOfMilestones	750000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Milestone Three Shares Cancelled CleneNanomedicineContingentEarnoutMilestoneThreeSharesCancelled	2503851
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63421908
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62312097
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4534000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-3351000
	us-gaap	Net Income Loss NetIncomeLoss	-17888000
	us-gaap	Net Income Loss NetIncomeLoss	-43107000
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63335271
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63335271
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61165018
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61165018
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63095400
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63095400
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60919340
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60919340
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
CY2022Q2	clnn	Convertible Notes Payables ConvertibleNotesPayables	482703
CY2021Q2	clnn	Convertible Notes Payables ConvertibleNotesPayables	482703
	clnn	Convertible Notes Payables ConvertibleNotesPayables	482703
	clnn	Convertible Notes Payables ConvertibleNotesPayables	482703
CY2022Q2	clnn	Common Stock Warrants CommonStockWarrants	4477045
CY2021Q2	clnn	Common Stock Warrants CommonStockWarrants	4562462
	clnn	Common Stock Warrants CommonStockWarrants	4477045
	clnn	Common Stock Warrants CommonStockWarrants	4562462
CY2022Q2	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	12071276
CY2021Q2	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	9128563
	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	12071276
	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	9128563
CY2022Q2	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	849215
CY2021Q2	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	1482815
	clnn	Unvested Restricted Stock Awards Shares UnvestedRestrictedStockAwardsShares	1482815
CY2022Q2	clnn	Unit Purchase Option Shares UnitPurchaseOptionShares	0
CY2021Q2	clnn	Unit Purchase Option Shares UnitPurchaseOptionShares	242000
	clnn	Unit Purchase Option Shares UnitPurchaseOptionShares	0
	clnn	Unit Purchase Option Shares UnitPurchaseOptionShares	242000
CY2022Q2	clnn	Earnoutshares Earnoutshares	6592334
CY2021Q2	clnn	Earnoutshares Earnoutshares	9096185
	clnn	Earnoutshares Earnoutshares	6592334
	clnn	Earnoutshares Earnoutshares	9096185
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	24472573
CY2021Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	24994728
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	24472573
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	24994728
CY2018Q3	clnn	Exclusive Rights Intellectual Property Term ExclusiveRightsIntellectualPropertyTerm	P5Y
CY2018Q3	clnn	Related Party Transaction Royalty Fee Rate For Revenues RelatedPartyTransactionRoyaltyFeeRateForRevenues	0.03
CY2022Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	33000
CY2021Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	200000
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	56000
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	402000
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10352000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9043000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17781000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4534000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3423000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17888000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43251000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8089000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2022Q2	us-gaap	Revenues Revenues	35000
CY2021Q2	us-gaap	Revenues Revenues	201000
	us-gaap	Revenues Revenues	65000
	us-gaap	Revenues Revenues	414000
CY2022Q2	us-gaap	Depreciation Depreciation	287000
CY2021Q2	us-gaap	Depreciation Depreciation	255000
	us-gaap	Depreciation Depreciation	482000
	us-gaap	Depreciation Depreciation	499000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13595000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13775000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26931000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25470000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13595000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13775000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26931000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25470000
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9061000
CY2022Q2	us-gaap	Assets Assets	44542000
CY2021Q4	us-gaap	Assets Assets	63063000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3399000
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	420000

Files In Submission

Name	View Source	Status
0000950170-22-017214-index-headers.html	Edgar Link	pending
0000950170-22-017214-index.html	Edgar Link	pending
0000950170-22-017214.txt	Edgar Link	pending
0000950170-22-017214-xbrl.zip	Edgar Link	pending
clnn-20220630.htm	Edgar Link	pending
clnn-20220630.xsd	Edgar Link	pending
clnn-20220630_cal.xml	Edgar Link	unprocessable
clnn-20220630_def.xml	Edgar Link	unprocessable
clnn-ex10_5.htm	Edgar Link	pending
clnn-ex10_6.htm	Edgar Link	pending
clnn-ex31_1.htm	Edgar Link	pending
clnn-ex31_2.htm	Edgar Link	pending
clnn-ex32_1.htm	Edgar Link	pending
clnn-ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img180854341_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
clnn-20220630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clnn-20220630_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
clnn-20220630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLNN
Clene Inc. Stock $clnn

2022 Q3 Form 10-Q Financial Statement

#000095017022017214 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN Clene Inc. Stock $clnn

2022 Q3 Form 10-Q Financial Statement

#000095017022017214 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN
Clene Inc. Stock $clnn